Ranolazine for Symptomatic Management of Microvascular Angina

Erin Rayner-Hartley,Mahraz Parvand,Karin H. Humphries,Andrew Starovoytov,Julie E. Park,Tara Sedlak

Ranolazine for Symptomatic Management of Microvascular Angina

2018

Erin Rayner-Hartley
Mahraz Parvand
Karin H. Humphries
Andrew Starovoytov
Julie E. Park
Tara Sedlak

Background:Ranolazine is approved in the United States and Europe for chronic stable angina. Microvascular angina (MVA) is defined as angina with no obstructive coronary artery disease.Study Question:Our objective was to assess the effectiveness of ranolazine at improving angina scores and quality o

Keywords:

Anesthesia
Diabetes mellitus
Medicine
Microvascular angina
Ranolazine
Coronary artery disease
Quality of life
Disease
Cohort
Internal medicine
Angina

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations